Matrix metalloproteinase -2, -9 and arterial stiffness in children and adolescents: The role of chronic kidney disease, diabetes, and hypertension.
Children
Chronic kidney disease
Diabetes
Hypertension
Matrix metalloproteinase
Pulse wave velocity
Journal
International Journal of Cardiology. Hypertension
ISSN: 2590-0862
Titre abrégé: Int J Cardiol Hypertens
Pays: Netherlands
ID NLM: 101773659
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
06
11
2019
revised:
30
01
2020
accepted:
02
02
2020
entrez:
15
1
2021
pubmed:
16
1
2021
medline:
16
1
2021
Statut:
epublish
Résumé
Matrix metalloproteinases (MMPs) may contribute to the pathogenesis of arterial stiffness inducing extracellular matrix remodeling. We aimed to compare MMP-2 and -9 levels in children with chronic kidney disease (CKD), type 1 diabetes (without chronic kidney disease) and healthy control and to investigate associations of MMPs levels with cardiovascular risk factors and markers of arterial stiffness. The study population included 33 CKD, 18 type 1 diabetes patients, and 24 healthy controls. MMP-2, MMP-9, office blood pressure, pulse wave analysis, and carotid-femoral pulse wave velocity (cfPWV) measurements were performed. MMP-2 levels were higher in the CKD compared to the diabetes and control groups (p < 0.05). MMP-9 levels did not differ among groups. In hypertensive individuals logMMP-2 independently associated with PWV z score (β = 0.744, 95%CI 0.105 to 2.921, MMP-2 associated with arterial stiffness in the presence of hypertension, while the role of MMP-9 is less clear in children with CKD or type 1 diabetes. Whether up-regulation of MMPs could predict poor outcomes in young high-risk patient groups need to be confirmed by future studies.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Matrix metalloproteinases (MMPs) may contribute to the pathogenesis of arterial stiffness inducing extracellular matrix remodeling. We aimed to compare MMP-2 and -9 levels in children with chronic kidney disease (CKD), type 1 diabetes (without chronic kidney disease) and healthy control and to investigate associations of MMPs levels with cardiovascular risk factors and markers of arterial stiffness.
METHODS
METHODS
The study population included 33 CKD, 18 type 1 diabetes patients, and 24 healthy controls. MMP-2, MMP-9, office blood pressure, pulse wave analysis, and carotid-femoral pulse wave velocity (cfPWV) measurements were performed.
RESULTS
RESULTS
MMP-2 levels were higher in the CKD compared to the diabetes and control groups (p < 0.05). MMP-9 levels did not differ among groups. In hypertensive individuals logMMP-2 independently associated with PWV z score (β = 0.744, 95%CI 0.105 to 2.921,
CONCLUSIONS
CONCLUSIONS
MMP-2 associated with arterial stiffness in the presence of hypertension, while the role of MMP-9 is less clear in children with CKD or type 1 diabetes. Whether up-regulation of MMPs could predict poor outcomes in young high-risk patient groups need to be confirmed by future studies.
Identifiants
pubmed: 33447754
doi: 10.1016/j.ijchy.2020.100025
pii: S2590-0862(20)30002-1
pmc: PMC7803037
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100025Informations de copyright
© 2020 The Authors.
Références
J Hypertens. 2016 Sep;34(9):1815-22
pubmed: 27379542
Metabolism. 2007 Jun;56(6):799-805
pubmed: 17512313
J Hypertens. 2019 Jan;37(1):30-36
pubmed: 29939943
Clin Biochem. 2011 Jul;44(10-11):838-43
pubmed: 21515251
Hypertension. 2009 Nov;54(5):919-50
pubmed: 19729599
Cardiovasc Res. 2007 May 1;74(2):196-206
pubmed: 17376414
Diabetes Care. 2010 Dec;33(12):2573-9
pubmed: 21115767
J Clin Res Pediatr Endocrinol. 2018 Nov 6;11(2):157-163
pubmed: 30396876
Pediatr Res. 2008 Jan;63(1):95-8
pubmed: 18043514
Cardiovasc Diabetol. 2017 Apr 26;16(1):55
pubmed: 28446168
Cardiovasc Diabetol. 2017 Oct 25;16(1):139
pubmed: 29070037
Int J Nephrol. 2016;2016:9498013
pubmed: 27042350
Semin Nephrol. 2018 Nov;38(6):559-569
pubmed: 30413251
Cell Stress Chaperones. 2011 Jan;16(1):97-103
pubmed: 20821177
Iran J Kidney Dis. 2018 May;12(3):169-177
pubmed: 29891747
Pediatr Nephrol. 2013 Jun;28(6):875-84
pubmed: 23070276
Hypertension. 2010 Aug;56(2):217-24
pubmed: 20566959
J Pediatr. 2010 May;156(5):731-7, 737.e1
pubmed: 20097360
Arch Intern Med. 2007 May 14;167(9):879-85
pubmed: 17502528
J Hypertens. 2012 Mar;30(3):445-8
pubmed: 22278144
Nephrol Dial Transplant. 2007 Oct;22(10):2909-16
pubmed: 17517792
Cardiovasc Res. 2009 Dec 1;84(3):494-504
pubmed: 19617223
J Am Soc Nephrol. 2004 Nov;15(11):2857-67
pubmed: 15504939
Pediatr Nephrol. 2013 Apr;28(4):583-93
pubmed: 23161206
Circulation. 2009 Sep 1;120(9):792-801
pubmed: 19687355
Pediatrics. 1976 Aug;58(2):259-63
pubmed: 951142
J Hypertens. 2015 Jan;33(1):88-95
pubmed: 25269016
Pharmacol Ther. 2019 Jan;193:99-120
pubmed: 30149103
Pediatr Diabetes. 2015 Feb;16(1):22-30
pubmed: 25604668
J Hypertens. 2016 Oct;34(10):1887-920
pubmed: 27467768
Atherosclerosis. 2007 Jan;190(1):199-204
pubmed: 16510149
Circ Res. 2002 Feb 22;90(3):251-62
pubmed: 11861412
PLoS One. 2013 Jul 26;8(7):e70132
pubmed: 23922934
Clin Sci (Lond). 2016 Apr 1;130(7):525-38
pubmed: 26733721
Clin Chim Acta. 2016 Jan 15;452:161-6
pubmed: 26612771